Ophthalmic CRO Target pharmaceutical and biotech companies developing ocular therapies who require preclinical in vivo and in vitro ophthalmic models, functional assessments, imaging, and molecular analysis services to de-risk Augen-related programs.

GLP Transition Position EXPERIMENTICA as aiming to offer GLP compliant ocular and general Safety & Toxicology studies, appealing to sponsors seeking compliant, high-quality data generation for regulatory submissions.

Global Collaboration Leverage existing facilities in Finland and Lithuania and past university collaborations to pursue joint programs with academic groups and biotech startups seeking contract research partners for early-stage ocular research and translational studies.

AI Enabled Highlight AI-driven image and data analysis capabilities to differentiate from competitors and attract clients needing advanced data interpretation, biomarker discovery, or enhanced readouts for ocular models.

Strategic Partnerships Capitalize on leadership joins and recent hires in digital transformation and business development to accelerate client acquisition, deepen partnerships, and expand global reach through targeted outreach at industry events like Life Sciences Baltics.